Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial

British Journal of Cancer
B VincenziG Tonini

Abstract

The epidermal growth factor receptor (EGFR), which participates in signalling pathways that are deregulated in cancer cells, is frequently mutated in colorectal-cancer cells. Cetuximab is a monoclonal antibody that specifically blocks the EGFR. We evaluated the efficacy of cetuximab in weekly combination with irinotecan in metastatic colorectal cancer patients refractory to previous treatments based on oxaliplatin or irinotecan. We included 55 heavily pretreated patients (colon/rectum: 34/11, M/F: 16/29, median age 63 years, range: 27-79) whose disease had progressed during or within an oxaliplatin-based first-line chemotherapy and a irinotecan-based second-line regimen. Patients were followed for tumour response and were also evaluated for the time to tumour progression, and safety of treatment. Cetuximab was given at an initial dose of 400 mg m(-2), followed by weekly infusions of 250 mg m(-2). Irinotecan was administered weekly at the dose of 90 mg m(-2). All patients were assessable for treatment efficacy and safety response rate was 25.4% (95% CI: 21.7-39.6%); 38.2% (95 CI: 18.6-39.8%) of patients showed a disease stability as the best response. As a consequence, the overall tumour control rate was 63.6% (95% CI: 46.4-70.6...Continue Reading

References

Jul 1, 1995·Critical Reviews in Oncology/hematology·D S SalomonN Normanno
Jan 7, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S GiacchettiF Lévi
Feb 5, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·T AndréA de Gramont
Aug 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A de GramontA Bonetti
Jun 29, 2001·Current Opinion in Oncology·A Grothey, H J Schmoll
Jan 7, 2003·Hematology/oncology Clinics of North America·Jose Baselga, Joan Albanell
Dec 11, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard M GoldbergSteven R Alberts
Mar 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Leonard B SaltzRobert J Mayer
Mar 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Axel GrotheyHans-Joachim Schmoll
Jul 23, 2004·The New England Journal of Medicine·David CunninghamEric Van Cutsem
Jan 29, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ki Young ChungLeonard B Saltz
May 28, 2005·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A P Dei Tos, I Ellis
Jul 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Román Peréz-Soler, Leonard Saltz

❮ Previous
Next ❯

Citations

Oct 10, 2006·Future Oncology·Danish MazharWolfgang Heller
Jan 1, 2009·Cancer Management and Research·Gunter SchuchCarsten Bokemeyer
Apr 5, 2011·Antioxidants & Redox Signaling·Laura A A Gilliam, Daret K St Clair
Mar 13, 2014·World Journal of Gastroenterology : WJG·Sally TemrazAli Shamseddine
Dec 1, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B VincenziG Tonini
Oct 18, 2011·Expert Review of Anticancer Therapy·Maria J LamasElena Gallardo
May 19, 2012·Expert Review of Anticancer Therapy·Vy Tuong BroadbridgeTimothy Jay Price
Mar 22, 2007·Expert Opinion on Biological Therapy·Steven M Sorscher
Oct 27, 2006·Expert Opinion on Emerging Drugs·Bruno VincenziGiuseppe Tonini
Apr 14, 2012·Drug Metabolism Reviews·Jose J G MarinOscar Briz
Feb 2, 2010·Clinical Journal of Oncology Nursing·Pamela Hallquist Viale
Jan 30, 2013·The EPMA Journal·Suzanne HaganBrendan Doyle
May 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter S KozuchHeinz-Josef Lenz
Mar 20, 2008·Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·C G FörsterF E Kruse
Aug 18, 2009·Journal of Experimental & Clinical Cancer Research : CR·Jeffrey B HoagMark E Lund
Mar 5, 2013·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Robert J Cersosimo
Sep 6, 2007·Cancer Chemotherapy and Pharmacology·M G GundgaardE Ehrnrooth
Feb 26, 2008·Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging·Lieven HuangTony Lahoutte
Feb 18, 2009·International Journal of Colorectal Disease·Emmanuel MitryPhilippe Rougier
Aug 17, 2010·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Jesús García-Foncillas, Eduardo Díaz-Rubio
Jan 5, 2012·British Journal of Cancer·C F JehnD Lüftner
Apr 25, 2012·Journal of Cancer Research and Clinical Oncology·S AbdelwahabA Mahmoud
Jan 1, 2008·The Oncologist·Christian WidakowichAhmad Awada
Mar 15, 2011·Oncotarget·Rajeev S Samant, Lalita A Shevde
Sep 3, 2019·Expert Review of Gastroenterology & Hepatology·Irem GulerIbrahim Halil Sahin
Feb 12, 2014·Asia-Pacific Journal of Clinical Oncology·Rod Sinclair
Oct 9, 2016·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Bernd TischerMario E Lacouture
Jul 1, 2016·Physiological Reviews·Jianchun ChenRaymond C Harris

❮ Previous
Next ❯

Methods Mentioned

BETA
imaging techniques

Software Mentioned

SPSS

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.